Abstract
Neurodegenerative diseases may directly affect memory performance, thus leading to functional impairments. An increasing body of evidence suggests an association between dietary intake of omega-3 fatty acids and memory functioning in animal models as well as in human studies. Recent evidence supports a potential beneficial role of omega-3 fatty acid supplementation on psychopathological and cognitive symptoms, beside their established positive effects on cardiovascular health.
Objective: We summarize relevant and recent evidence from epidemiological, interventional and experimental studies investigating dietary consumption of omega-3 fatty acids and emphazing mechanisms of memory disorders, with a focus on mild cognitive impairment (MCI) and dementia. Omega-3 fatty acid could represent an affordable and accessible adjunctive treatment option to improve cognitive and non-cognitive function with a focus on MCI or dementia. However, apart from its translational promise, which is based on mechanistic models and evidence from animal studies, evidence for clinical benefits in humans is lacking. Method: To follow this research question, a search through electronic databases for the following search terms to identify relevant studies was conducted: ‘omega 3 fatty acids’, ‘cognition’, ‘memory’, ´Alzheimer´s Disease ´, ´dementia´, ´MCI`. Studies were included if they presented original data and were published in English between 1990 and 2015. Results: To our the best of our knowledge, there are only 8 interventional studies that investigated the effects of n3-PUFAs in dementia patients, while 6 studies were conducted in healthy individuals, which in combination show equivocal results. Conclusion: This verifies the need for larger and (more) well designed clinical trials.Keywords: Omega 3 fatty acids, psychiatric disorders, cognition, Alzheimer's dementia, MCI.
Current Alzheimer Research
Title:Omega-3 Fatty Acids: Repurposing Opportunities for Cognition and Biobehavioral Disturbances in MCI and Dementia
Volume: 14 Issue: 3
Author(s): Christian Knöchel, Martin Voss, Florian Gruter, Gilberto S. Alves, Silke Matura, Beate Sepanski, Michael Stablein, Dominik Kraft, David Prvulovic, Andre F. Carvalho, Andreas Reif and Viola Oertel-Knochel
Affiliation:
Keywords: Omega 3 fatty acids, psychiatric disorders, cognition, Alzheimer's dementia, MCI.
Abstract: Neurodegenerative diseases may directly affect memory performance, thus leading to functional impairments. An increasing body of evidence suggests an association between dietary intake of omega-3 fatty acids and memory functioning in animal models as well as in human studies. Recent evidence supports a potential beneficial role of omega-3 fatty acid supplementation on psychopathological and cognitive symptoms, beside their established positive effects on cardiovascular health.
Objective: We summarize relevant and recent evidence from epidemiological, interventional and experimental studies investigating dietary consumption of omega-3 fatty acids and emphazing mechanisms of memory disorders, with a focus on mild cognitive impairment (MCI) and dementia. Omega-3 fatty acid could represent an affordable and accessible adjunctive treatment option to improve cognitive and non-cognitive function with a focus on MCI or dementia. However, apart from its translational promise, which is based on mechanistic models and evidence from animal studies, evidence for clinical benefits in humans is lacking. Method: To follow this research question, a search through electronic databases for the following search terms to identify relevant studies was conducted: ‘omega 3 fatty acids’, ‘cognition’, ‘memory’, ´Alzheimer´s Disease ´, ´dementia´, ´MCI`. Studies were included if they presented original data and were published in English between 1990 and 2015. Results: To our the best of our knowledge, there are only 8 interventional studies that investigated the effects of n3-PUFAs in dementia patients, while 6 studies were conducted in healthy individuals, which in combination show equivocal results. Conclusion: This verifies the need for larger and (more) well designed clinical trials.Export Options
About this article
Cite this article as:
Knöchel Christian, Voss Martin, Gruter Florian, Alves S. Gilberto, Matura Silke, Sepanski Beate, Stablein Michael, Kraft Dominik, Prvulovic David, Carvalho F. Andre, Reif Andreas and Oertel-Knochel Viola, Omega-3 Fatty Acids: Repurposing Opportunities for Cognition and Biobehavioral Disturbances in MCI and Dementia, Current Alzheimer Research 2017; 14 (3) . https://dx.doi.org/10.2174/1567205013666160602235520
DOI https://dx.doi.org/10.2174/1567205013666160602235520 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Early and Mild Phases of Primary Progressive Aphasia: A Case Series
Current Aging Science Editorial (Thematic Issue: Cell Metabolism and Current Challenges in Drug Research)
Current Pharmaceutical Design Association between ALDH2 Gene Polymorphism and Late-onset Alzheimer Disease: An Up-to-date Meta-analysis
Current Alzheimer Research Antiplatelet Therapy in Acute Coronary Syndromes. Evidence Based Medicine
Current Pharmaceutical Design Oligomeric Amyloid β -Protein as a Therapeutic Target in Alzheimers Disease: Its Significance Based on its Distinct Localization and the Occurrence of a Familial Variant Form
Current Alzheimer Research Posttranslational Modifications of Tau - Role in Human Tauopathies and Modeling in Transgenic Animals
Current Drug Targets Candidate Circulating Biomarkers for the Cardiovascular Disease Continuum
Current Pharmaceutical Design The Intracellular Domain of Amyloid Precursor Protein is a Potential Therapeutic Target in Alzheimer’s Disease
Current Drug Discovery Technologies Alzheimers Disease: Targets For Drug Development
Mini-Reviews in Medicinal Chemistry Nonhuman Primate Models of Alzheimer-Like Cerebral Proteopathy
Current Pharmaceutical Design Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Relationship Between Inflammation, Platelet Activation and Antiplatelet Resistance
Inflammation & Allergy - Drug Targets (Discontinued) Erythropoietin: Cytoprotection in Vascular and Neuronal Cells
Current Drug Targets - Cardiovascular & Hematological Disorders Therapeutic Development of Interrelated Metabolic and Neurodegenerative Disorders
Current Pharmaceutical Design Resurrecting Clinical Pharmacology As a Context for Alzheimer Disease Drug Development
Current Alzheimer Research Diabetes Mellitus and Vascular Endothelial Dysfunction: Current Perspectives
Current Vascular Pharmacology Oleanolic Acid and Related Triterpenoids from Olives on Vascular Function: Molecular Mechanisms and Therapeutic Perspectives
Current Medicinal Chemistry Novel Kynurenic Acid Analogues in the Treatment of Migraine and Neurodegenerative Disorders: Preclinical Studies and Pharmaceutical Design
Current Pharmaceutical Design A Review on Novel Ligand Targeted Delivery for Cardiovascular Disorder
Current Drug Delivery Multiple Species Metabolism of PHA-568487, A Selective α7 Nicotinic Acetylcholine Receptor Agonist
Drug Metabolism Letters